Pharmosa Biopharm Inc.
Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Li… Read more
Market Cap & Net Worth: Pharmosa Biopharm Inc. (6875)
Pharmosa Biopharm Inc. (TWO:6875) has a market capitalization of $157.43 Million (NT$5.21 Billion) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #18522 globally and #859 in its home market, demonstrating a 1.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharmosa Biopharm Inc.'s stock price NT$40.35 by its total outstanding shares 129086404 (129.09 Million).
Pharmosa Biopharm Inc. Market Cap History: 2022 to 2026
Pharmosa Biopharm Inc.'s market capitalization history from 2022 to 2026. Data shows change from $247.75 Million to $157.43 Million (-4.31% CAGR).
Pharmosa Biopharm Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharmosa Biopharm Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.09x
Pharmosa Biopharm Inc.'s market cap is 1.09 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
40.60x
Pharmosa Biopharm Inc.'s market cap is 40.60 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $343.33 Million | $314.50 Million | $8.46 Million | 1.09x | 40.60x |
Competitor Companies of 6875 by Market Capitalization
Companies near Pharmosa Biopharm Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Pharmosa Biopharm Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Pharmosa Biopharm Inc. Historical Marketcap From 2022 to 2026
Between 2022 and today, Pharmosa Biopharm Inc.'s market cap moved from $247.75 Million to $ 157.43 Million, with a yearly change of -4.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$157.43 Million | -22.25% |
| 2025 | NT$202.49 Million | -1.89% |
| 2024 | NT$206.39 Million | -39.89% |
| 2023 | NT$343.33 Million | +38.58% |
| 2022 | NT$247.75 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Pharmosa Biopharm Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $157.43 Million USD |
| MoneyControl | $157.43 Million USD |
| MarketWatch | $157.43 Million USD |
| marketcap.company | $157.43 Million USD |
| Reuters | $157.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.